<DOC>
	<DOCNO>NCT01309438</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics pharmacodynamics rivaroxaban administer erythromycin study participant mild moderate renal impairment compare pharmacokinetics pharmacodynamics rivaroxaban administer study participant normal renal function .</brief_summary>
	<brief_title>A Study Erythromycin Rivaroxaban Study Participants With Normal Reduced Kidney Function</brief_title>
	<detailed_description>This open-label study ( participant study physician [ Investigator ] know identity assign treatment ) compare pharmacokinetics ( PK ) ( drug absorb body ) pharmacodynamics ( PD ) ( action effect drug body ) rivaroxaban study participant mild moderate renal impairment ( reduce kidney function ) receive multiple dos erythromycin , PK PD single dose rivaroxaban administer alone study participant normal renal function . The study drug use rivaroxaban , drug act thin blood prevent formation blood clot , erythromycin , antibiotic use treat patient bacterial infection . Study participant normal renal function receive Treatment A ( 1 oral [ mouth ] dose 10 mg rivaroxaban 1 day ) Treatment C ( 500 mg oral erythromycin 3x day ( t.i.d . ) Days 1-6 + 1 oral dose 10 mg rivaroxaban Day 5 ) . Study participant mild moderate renal impairment receive Treatment A , Treatment B ( 500 mg oral erythromycin t.i.d . Days 1-6 + 1 oral dose 5 mg rivaroxaban Day 5 ) , Treatment C. Treatments A , B , C separate 14 day .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<criteria>Have body mass index ( BMI ) 18 38 kg/m2 , inclusive Have body weight less 50 kg characterize normal renal function ( creatinine clearance [ CLCR ] &gt; 80 mL/min ) , mild renal impairment ( CLCR 5079 mL/min ) moderate renal impairment ( CLCR 3049 mL/min ) Study participant renal impairment stable renal disease determine Investigator History current clinically significant medical illness illness Investigator considers exclude study participant could interfere interpretation study result Additional exclusion criterion study participant normal renal function include : diastolic blood pressure &gt; 95 mm Hg and/or systolic blood pressure &gt; 150 mm Hg ) Additional exclusion criterion study participant renal impairment include : diastolic blood pressure &gt; 100 mm Hg and/or systolic blood pressure &gt; 170 mm Hg , routine laboratory parameter &gt; upper limit normal could explain underlying renal disease unless judge clinically unimportant investigator , acute renal failure , recipient transplant organ Have severe renal impairment ( CLCR &lt; 30 mL/min )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Rivaroxaban ( BAY 59-7939 , JNJ-39039039 )</keyword>
	<keyword>Erythromycin</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
</DOC>